Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.

Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJelle, Molinuevo JLuis, Verhey FRJ, Winblad B

J Alzheimers Dis. 2017; 60(4):1477-1487. PMID: 29081416. Abstract